<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-42001" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dipeptidyl Peptidase IV (DPP IV) Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasina</surname>
            <given-names>Srinivasa Venkata Siva Kumar</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baradhi</surname>
            <given-names>Krishna M.</given-names>
          </name>
          <aff>University of Oklahoma</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Srinivasa Venkata Siva Kumar Kasina declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Krishna Baradhi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-42001.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Dipeptidyl peptidase 4 (DPP-4) inhibitors are a group of antihyperglycemic medications used to manage type 2 diabetes mellitus, which is a significant risk factor for coronary disease, heart failure, stroke, and many other cardiovascular conditions. This activity reviews the various drugs in this group, indications, contraindications, activity, adverse events, and other key elements of DPP-4 inhibitors therapy in the clinical setting. It also elaborates on the essential information needed by any interprofessional team member managing the care of patients with diabetes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of dipeptidyl peptidase 4 (DPP-4) inhibitors.</p></list-item><list-item><p>Describe the potential adverse effects of dipeptidyl peptidase 4 (DPP-4) inhibitors.</p></list-item><list-item><p>Review the appropriate monitoring of dipeptidyl peptidase 4 (DPP-4) inhibitors.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance diabetes management and improve outcomes using DPP-4 inhibitors.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42001&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42001">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-42001.s2" sec-type="Indications">
        <title>Indications</title>
        <p>DPP-4 inhibitors, known as gliptins, are a class of oral diabetic&#x000a0;medications approved by the Food and Drug Administration (FDA) to treat type 2 diabetes mellitus in adults.</p>
        <p>DPP-4 inhibitors that have&#x000a0;FDA approval&#x000a0;include sitagliptin, saxagliptin, linagliptin, and alogliptin. Vildagliptin has approval from the European Medicines Agency (EMA), but not by the FDA.</p>
        <p>These drugs act through incretin hormones, which are gut hormones responsible for glucose homeostasis after oral food intake.</p>
        <p>Apart from antihyperglycemic effects, this class of drugs possesses antihypertensive effects, anti-inflammatory effects, antiapoptotic effects, and immunomodulatory effects on the heart, kidneys, and blood vessels independent of the incretin pathway.<xref ref-type="bibr" rid="article-42001.r1">[1]</xref> Some studies&#x000a0;have shown that this class of drugs could also be used in kidney and liver transplant recipients with new-onset diabetes after transplantation (NODAT) due to all these benefits.<xref ref-type="bibr" rid="article-42001.r1">[1]</xref></p>
        <p>They can be used as monotherapy or add-on therapy with other medications.<xref ref-type="bibr" rid="article-42001.r2">[2]</xref><xref ref-type="bibr" rid="article-42001.r3">[3]</xref> Options for add-on therapy include metformin,&#x000a0;sulfonylureas,&#x000a0;thiazolidinediones,&#x000a0;or insulin.<xref ref-type="bibr" rid="article-42001.r4">[4]</xref><xref ref-type="bibr" rid="article-42001.r5">[5]</xref><xref ref-type="bibr" rid="article-42001.r6">[6]</xref><xref ref-type="bibr" rid="article-42001.r7">[7]</xref><xref ref-type="bibr" rid="article-42001.r8">[8]</xref></p>
      </sec>
      <sec id="article-42001.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>DPP-4 is a ubiquitous enzyme that acts on incretin hormones, mainly GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory peptide), which maintain glucose homeostasis by increasing insulin secretion and decreasing glucagon secretion.<xref ref-type="bibr" rid="article-42001.r9">[9]</xref></p>
        <p>GLP-1 is a hormone secreted by enteroendocrine L cells of the small intestine, which lowers blood glucose by stimulating insulin secretion, reducing glucagon concentrations, and delaying gastric emptying.<xref ref-type="bibr" rid="article-42001.r10">[10]</xref> It has a half-life of&#x000a0;fewer than 2 minutes.<xref ref-type="bibr" rid="article-42001.r11">[11]</xref>&#x000a0;GIP is a hormone secreted in the stomach and proximal small intestine by neuroendocrine K-cells. Its half-life is approximately 7 minutes in healthy individuals and 5 minutes in individuals with type 2 diabetes.<xref ref-type="bibr" rid="article-42001.r11">[11]</xref></p>
        <p>These incretins are released within minutes of food intake, and DPP-4 degrades these hormones immediately due to their short half-life.&#x000a0;By inhibiting the DPP-4 enzyme, DPP-4 inhibitors increase the levels of GLP-1 and GIP, which in turn increase beta-cell insulin secretion in the pancreas, thereby reducing postprandial and fasting hyperglycemia.<xref ref-type="bibr" rid="article-42001.r9">[9]</xref></p>
      </sec>
      <sec id="article-42001.s4" sec-type="Administration">
        <title>Administration</title>
        <p>All the DPP-4 inhibitors are administered orally, once daily, before or after meals.</p>
        <p>A study of oral and intravenous administration of sitagliptin in healthy individuals demonstrated an 87% oral bioavailability.<xref ref-type="bibr" rid="article-42001.r10">[10]</xref></p>
      </sec>
      <sec id="article-42001.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Gliptins are associated with a low incidence of adverse events, including hypoglycemia, and have weight-neutral effects. However, the risk of hypoglycemia increases when used in conjunction with sulfonylureas.<xref ref-type="bibr" rid="article-42001.r12">[12]</xref></p>
        <p>The most common side effects noticed with the DPP-4 inhibitors sitagliptin and saxagliptin are upper respiratory tract infection, nasopharyngitis, headache, urinary tract infection, arthralgia.<xref ref-type="bibr" rid="article-42001.r10">[10]</xref>&#x000a0;There are also reports of hypersensitivity reactions such as anaphylaxis and angioedema in the prescribing information of most DPP-4 inhibitors.<xref ref-type="bibr" rid="article-42001.r13">[13]</xref> Sitagliptin was also associated with Stevens-Johnson syndrome in postmarketing reports.<xref ref-type="bibr" rid="article-42001.r10">[10]</xref>&#x000a0;Reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing variants, have correlations with the use of sitagliptin, vildagliptin, and saxagliptin in postmarketing data.<xref ref-type="bibr" rid="article-42001.r13">[13]</xref> However, a causal relationship remains unproven with the use of gliptins and pancreatitis.<xref ref-type="bibr" rid="article-42001.r14">[14]</xref>&#x000a0;There has also been a case series&#x000a0;published in Japan of four patients who had acquired hemophilia A in patients using DPP-4 inhibitors.<xref ref-type="bibr" rid="article-42001.r15">[15]</xref></p>
        <p>DPP-4 inhibitors (alogliptin, sitagliptin, saxagliptin, linagliptin) did not show an increased risk of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke when compared to placebo in patients with type 2 diabetes,&#x000a0;although saxagliptin had an association with an increased rate of hospitalization for heart failure.<xref ref-type="bibr" rid="article-42001.r16">[16]</xref><xref ref-type="bibr" rid="article-42001.r17">[17]</xref><xref ref-type="bibr" rid="article-42001.r18">[18]</xref><xref ref-type="bibr" rid="article-42001.r19">[19]</xref></p>
      </sec>
      <sec id="article-42001.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to gliptins include type 1 diabetes and diabetic ketoacidosis.&#x000a0;Sitagliptin is contraindicated in individuals who are sensitive to the drug or its components. Caution is necessary when using gliptins in patients with a history of pancreatitis; it would be reasonable to discontinue these drugs if pancreatitis is suspected.<xref ref-type="bibr" rid="article-42001.r10">[10]</xref></p>
        <p>Dose adjustments are necessary for patients with renal insufficiency taking sitagliptin and saxagliptin as these drugs undergo renal excretion; failure to adjust the dose could increase the chance of hypoglycemia.<xref ref-type="bibr" rid="article-42001.r10">[10]</xref></p>
      </sec>
      <sec id="article-42001.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>DPP-4 inhibitors have minimal to no interactions with other drugs because of their pharmacokinetic properties, the exception being saxagliptin. Saxagliptin is metabolized to its active form by CYP3A4/5; hence the levels of the drug and its active metabolite might be modified when administered along with drugs affecting CYP3A4/5 isoforms such as ketoconazole, diltiazem (inhibitors of CYP3A4/5), or rifampicin (inducer of CYP3A4/5). Dose adjustments of saxagliptin may be necessary for such instances.<xref ref-type="bibr" rid="article-42001.r20">[20]</xref></p>
        <p>The package insert of sitagliptin mentions the need for close monitoring when using in conjunction with digoxin as the former causes a small increase (11%) in the area under the curve (AUC) and plasma Cmax (18%) of digoxin. However, dose adjustment is not a recommendation.&#x000a0;The patient's renal function requires monitoring after initiating therapy with either sitagliptin or saxagliptin in addition to glycemic control.<xref ref-type="bibr" rid="article-42001.r10">[10]</xref></p>
      </sec>
      <sec id="article-42001.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Clinical trials showed no adverse drug reactions using very high doses of saxagliptin, alogliptin, linagliptin. However, high doses of sitagliptin were associated with an 8.0-millisecond mean increase in QTc in controlled clinical trials as labeled by the FDA. In case of overdose, hemodialysis removes approximately 13% of sitagliptin and approximately 23% of saxagliptin but did not affect alogliptin or linagliptin.</p>
      </sec>
      <sec id="article-42001.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team approach is critical in controlling diabetes and its complications. It requires providers (primary care physician, endocrinologist, ophthalmologist, podiatrist), pharmacists, nurse practitioners, dieticians, and diabetes educator nurses to collaborate as an interprofessional team in providing care. Literature indicates that such a collaborative effect can improve diabetic management, lower the risk of chronic disease complications. [Level 5]</p>
        <list list-type="bullet">
          <list-item>
            <p>Health care providers can emphasize the importance of metabolic control and other cardiovascular risk factors, promote healthy lifestyle practices, including physical activity and healthful eating, and explain the benefits of comprehensive team care.</p>
          </list-item>
          <list-item>
            <p>Diabetes nurse educators and dieticians provide education to the patient in improving the patient's weight loss and A1c values with ideal diet and nutrition.</p>
          </list-item>
          <list-item>
            <p>Pharmacists can collaborate with patients and their physicians to improve clinical measures, lower health care costs, and making sure that the drugs are in an affordable range to the patient by communicating with the patient's insurance companies.</p>
          </list-item>
          <list-item>
            <p>Recognizing danger signs of foot and eye problems and referral to an appropriate provider can be done by any team member. Various health care providers can obtain a referral for regular screening.</p>
          </list-item>
          <list-item>
            <p>Specialist providers such as podiatrists, ophthalmologists can help reduce lower extremity amputation rates in foot care clinics, prevent blindness, respectively.</p>
          </list-item>
        </list>
        <p>National Diabetes Education Program (NDEP), a federally sponsored initiative of the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), is committed to working with public and private partners in preventing or delaying the onset of type 2 diabetes, promoting early diagnosis, improve treatment and outcomes for people with diabetes. It also offers resources to help healthcare professionals implement collaborative, interprofessional diabetes team care in a variety of settings.</p>
      </sec>
      <sec id="article-42001.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=42001&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=42001">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/42001/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=42001">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-42001.s11">
        <title>References</title>
        <ref id="article-42001.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation.</article-title>
            <source>Korean J Intern Med</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>759</fpage>
            <page-range>759-70</page-range>
            <pub-id pub-id-type="pmid">26552451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charbonnel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Karasik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meininger</surname>
                <given-names>G</given-names>
              </name>
              <collab>Sitagliptin Study 020 Group</collab>
            </person-group>
            <article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.</article-title>
            <source>Diabetes Care</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>12</issue>
            <fpage>2638</fpage>
            <page-range>2638-43</page-range>
            <pub-id pub-id-type="pmid">17130197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Camisasca</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Collober</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rochotte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.</article-title>
            <source>Diabetes Care</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>890</fpage>
            <page-range>890-5</page-range>
            <pub-id pub-id-type="pmid">17277036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeFronzo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hissa</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Luiz Gross</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yuyan Duan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ravichandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>RS</given-names>
              </name>
              <collab>Saxagliptin 014 Study Group</collab>
            </person-group>
            <article-title>The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.</article-title>
            <source>Diabetes Care</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>1649</fpage>
            <page-range>1649-55</page-range>
            <pub-id pub-id-type="pmid">19478198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hermansen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kipnes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fanurik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khatami</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>P</given-names>
              </name>
              <collab>Sitagliptin Study 035 Group</collab>
            </person-group>
            <article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>733</fpage>
            <page-range>733-45</page-range>
            <pub-id pub-id-type="pmid">17593236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brazg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andryuk</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>P</given-names>
              </name>
              <collab>Sitagliptin Study 019 Group</collab>
            </person-group>
            <article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.</article-title>
            <source>Clin Ther</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1556</fpage>
            <page-range>1556-68</page-range>
            <pub-id pub-id-type="pmid">17157112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garber</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Schweizer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rochotte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dejager</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>166</fpage>
            <page-range>166-74</page-range>
            <pub-id pub-id-type="pmid">17300592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fonseca</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schweizer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Albrecht</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dejager</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.</article-title>
            <source>Diabetologia</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>1148</fpage>
            <page-range>1148-55</page-range>
            <pub-id pub-id-type="pmid">17387446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capuano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sportiello</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maiorino</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2013</year>
            <volume>7</volume>
            <fpage>989</fpage>
            <page-range>989-1001</page-range>
            <pub-id pub-id-type="pmid">24068868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pathak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bridgeman</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes.</article-title>
            <source>P T</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>509</fpage>
            <page-range>509-13</page-range>
            <pub-id pub-id-type="pmid">20975810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Choosing a gliptin.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>298</fpage>
            <page-range>298-308</page-range>
            <pub-id pub-id-type="pmid">22029001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Arnaud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Raschi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Ponti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>B&#x000e9;gaud</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pariente</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2016</year>
            <month>May</month>
            <day>03</day>
            <volume>353</volume>
            <fpage>i2231</fpage>
            <pub-id pub-id-type="pmid">27142267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karagiannis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boura</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tsapas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety of dipeptidyl peptidase 4 inhibitors: a perspective review.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>138</fpage>
            <page-range>138-46</page-range>
            <pub-id pub-id-type="pmid">25083269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montilla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marchesini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sammarco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trotta</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Siviero</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Tomino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Melchiorri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>L</given-names>
              </name>
              <collab>AIFA Anti-diabetics Monitoring Group</collab>
            </person-group>
            <article-title>Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.</article-title>
            <source>Nutr Metab Cardiovasc Dis</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>1346</fpage>
            <page-range>1346-53</page-range>
            <pub-id pub-id-type="pmid">25300980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamasaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kadowaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jiromaru</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Acquired Hemophilia A Associated with Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Single-Center Case Series in Japan.</article-title>
            <source>Diabetes Ther</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>1139</fpage>
            <page-range>1139-1143</page-range>
            <pub-id pub-id-type="pmid">30927215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bethel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Josse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Koglin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Korn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lachin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Pencina</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Standl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Suryawanshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van de Werf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>RR</given-names>
              </name>
              <collab>TECOS Study Group</collab>
            </person-group>
            <article-title>Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jul</month>
            <day>16</day>
            <volume>373</volume>
            <issue>3</issue>
            <fpage>232</fpage>
            <page-range>232-42</page-range>
            <pub-id pub-id-type="pmid">26052984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Pencina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toto</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Woerle</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Baanstra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pfarr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schnaidt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meinicke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>von Eynatten</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <collab>CARMELINA Investigators</collab>
            </person-group>
            <article-title>Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>321</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-79</page-range>
            <pub-id pub-id-type="pmid">30418475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bergenstal</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Fleck</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Kupfer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <collab>EXAMINE Investigators</collab>
            </person-group>
            <article-title>Alogliptin after acute coronary syndrome in patients with type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Oct</month>
            <day>03</day>
            <volume>369</volume>
            <issue>14</issue>
            <fpage>1327</fpage>
            <page-range>1327-35</page-range>
            <pub-id pub-id-type="pmid">23992602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scirica</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirshberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frederich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Cavender</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Udell</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Mosenzon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Raz</surname>
                <given-names>I</given-names>
              </name>
              <collab>SAVOR-TIMI 53 Steering Committee and Investigators</collab>
            </person-group>
            <article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Oct</month>
            <day>03</day>
            <volume>369</volume>
            <issue>14</issue>
            <fpage>1317</fpage>
            <page-range>1317-26</page-range>
            <pub-id pub-id-type="pmid">23992601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-42001.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>573</fpage>
            <page-range>573-88</page-range>
            <pub-id pub-id-type="pmid">20690781</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
